ArticlemBio2012
Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?
Article in mBio, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Mechanisms and Impact of Biofilms and Targeting of Biofilms Using Bioactive Compounds-A Review.Medicina (Kaunas, Lithuania) · 2021Review
- Gallium(III)-Salophen as a Dual Inhibitor ofACS infectious diseases · 2020Article
- Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.Antimicrobial agents and chemotherapy · 2016Article
- Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.PloS one · 2015Article
- Clostridium difficile phages: still difficult?Frontiers in microbiology · 2014Review
- Article
- Applying insights from biofilm biology to drug development - can a new approach be developed?Nature reviews. Drug discovery · 2013Review
- Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.Microbiology insights · 2013Review
- The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.PloS one · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In contrast to usual laboratory conditions, most bacteria in the human body grow in biofilms. Encased in a structured matrix, many pathogens display heightened resistance to antibiotics. Pseudomonas aeruginosa lung infections in cystic fibrosis patients represent a prime example of the clinical challenges that antibiotic resistance in biofilms can represent. In the March 6, 2012 issue of mBio, Colin Hill and his colleagues report on experiments that add to the evidence that Pseudomonas phages are a potential treatment option for these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.